Search Results - "Chartash, Elliot"

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma by Nghiem, Paul T, Bhatia, Shailender, Lipson, Evan J, Kudchadkar, Ragini R, Miller, Natalie J, Annamalai, Lakshmanan, Berry, Sneha, Chartash, Elliot K, Daud, Adil, Fling, Steven P, Friedlander, Philip A, Kluger, Harriet M, Kohrt, Holbrook E, Lundgren, Lisa, Margolin, Kim, Mitchell, Alan, Olencki, Thomas, Pardoll, Drew M, Reddy, Sunil A, Shantha, Erica M, Sharfman, William H, Sharon, Elad, Shemanski, Lynn R, Shinohara, Michi M, Sunshine, Joel C, Taube, Janis M, Thompson, John A, Townson, Steven M, Yearley, Jennifer H, Topalian, Suzanne L, Cheever, Martin A

“…Merkel-cell carcinoma is an aggressive neuroendocrine tumor that is poorly responsive to chemotherapy. In a small series of patients, pembrolizumab produced…”
Get full text

Vaccine Responses in Patients with Rheumatoid Arthritis Treated with Certolizumab Pegol: Results from a Single-blind Randomized Phase IV Trial by KIVITZ, Alan J, SCHECHTMAN, Joy, TEXTER, Michele, FICHTNER, Andreas, DE LONGUEVILLE, Marc, CHARTASH, Elliot K

“…To evaluate the humoral immune response to pneumococcal and influenza vaccination in adults with rheumatoid arthritis (RA) receiving certolizumab pegol (CZP)…”
Get full text

Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study by Cohen, Graham, Rapoport, Bernardo, Chan, Sze W, Ruff, Paul, Arance, Ana, Mujika Eizmendi, Karmele, Houghton, Baerin, Brown, Michael P, Zielinski, Robert M, Muñoz Couselo, Eva, Lyle, Megan, Anderson, James R, Jain, Lokesh, de Alwis, Dinesh, Lala, Mallika, Akala, Omobolaji, Chartash, Elliot, Jacobs, Conrad

“…Intravenous pembrolizumab 400 mg every 6 weeks was approved across tumor types based on pharmacokinetic modeling, which showed exposures consistent with…”
Get full text

Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis by CELLA, David, YOUNT, Susan, SORENSEN, Mark, CHARTASH, Elliot, SENGUPTA, Nishan, GROBER, James

“…OBJECTIVE: This study validated a brief measure of fatigue in rheumatoid arthritis (RA), the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue…”
Get full text

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis) by FURST, Daniel E, SCHIFF, Michael H, FLEISCHMANN, Roy M, STRAND, Vibeke, BIRBARA, Charles A, COMPAGNONE, Daniele, FISCHKOFF, Steven A, CHARTASH, Elliot K

“…OBJECTIVE: This study, known as STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis), evaluated the safety and efficacy of adalimumab (Humira), a fully…”
Get full text

Preclinical characterization and clinical translation of pharmacodynamic markers for MK-5890: a human CD27 activating antibody for cancer immunotherapy by Guelen, Lars, Fischmann, Thierry O, Wong, Jerelyn, Mauze, Smita, Guadagnoli, Marco, Bąbała, Nikolina, Wagenaars, Jozef, Juan, Veronica, Rosen, David, Prosise, Winnie, Habraken, Maurice, Lodewijks, Imke, Gu, Danling, Stammen-Vogelzangs, Judith, Yu, Ying, Baker, Jeanne, Lutje Hulsik, David, Driessen-Engels, Lilian, Malashock, Dan, Kreijtz, Joost, Bertens, Astrid, de Vries, Evert, Bovens, Astrid, Bramer, Arne, Zhang, Yiwei, Wnek, Richard, Troth, Sean, Chartash, Elliot, Dobrenkov, Konstantin, Sadekova, Svetlana, van Elsas, Andrea, Cheung, Jason K, Fayadat-Dilman, Laurence, Borst, Jannie, Beebe, Amy M, Van Eenennaam, Hans

“…BackgroundImmune checkpoint inhibitors (ICI) have radically changed cancer therapy, but most patients with cancer are unresponsive or relapse after treatment…”
Get full text

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study by Weisman, Michael H., Moreland, Larry W., Furst, Daniel E., Weinblatt, Michael E., Keystone, Edward C., Paulus, Harold E., Teoh, Leah S., Velagapudi, Raja B., Noertersheuser, Peter A., Granneman, G.Richard, Fischkoff, Steven A., Chartash, Elliot K.

“…Background: Because traditional therapies for rheumatoid arthritis (RA) such as methotrexate (MTX) do not produce an adequate response in many patients, newer…”
Get full text

A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation by Lala, Mallika, Li, Tommy Ruosi, de Alwis, Dinesh P., Sinha, Vikram, Mayawala, Kapil, Yamamoto, Noboru, Siu, Lillian L., Chartash, Elliot, Aboshady, Hesham, Jain, Lokesh

“…Pembrolizumab is approved for multiple cancer types at 200 mg and 2 mg/kg dose every 3 weeks (Q3W). We used a model-based approach to compare the exposure of…”
Get full text

First‐in‐human phase 1 study of MK‐1248, an anti–glucocorticoid‐induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors by Geva, Ravit, Voskoboynik, Mark, Dobrenkov, Konstantin, Mayawala, Kapil, Gwo, Jennifer, Wnek, Richard, Chartash, Elliot, Long, Georgina V.

“…Background Ligation of glucocorticoid‐induced tumor necrosis factor receptor (GITR) decreases regulatory T cell–mediated suppression and enhances T‐cell…”
Get full text

Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial by Kimball, Alexa B, Gordon, Kenneth B, Langley, Richard G, Menter, Alan, Chartash, Elliot K, Valdes, Joaquin

“…To investigate the efficacy and safety of ABT-874, an interleukin 12/23 monoclonal antibody, in psoriasis. Phase 2, 12-week, multicenter, randomized,…”
Get more information

Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors by Papadopoulos, Kyriakos P, Autio, Karen, Golan, Talia, Dobrenkov, Konstantin, Chartash, Elliot, Chen, Qiusheng, Wnek, Richard, Long, Georgina V

“…In this first-in-human phase I study (NCT02132754), we explored MK-4166 [humanized IgG1 agonist mAb targeting glucocorticoid-induced TNF receptor (GITR)] with…”
Get full text

Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial by Weinblatt, Michael E., Keystone, Edward C., Furst, Daniel E., Moreland, Larry W., Weisman, Michael H., Birbara, Charles A., Teoh, Leah A., Fischkoff, Steven A., Chartash, Elliot K.

“…Objective To evaluate the efficacy and safety of adalimumab (D2E7), a fully human monoclonal tumor necrosis factor α antibody, in combination with methotrexate…”
Get full text

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trial by Keystone, Edward C., Kavanaugh, Arthur F., Sharp, John T., Tannenbaum, Hyman, Hua, Ye, Teoh, Leah S., Fischkoff, Steven A., Chartash, Elliot K.

“…Objective Tumor necrosis factor (TNF) is an important proinflammatory cytokine that mediates inflammatory synovitis and articular matrix degradation in…”
Get full text

Phase I Study of MK-4166, an Anti-Human Glucocorticoid-Induced Tumor Necrosis Factor Receptor Antibody, Alone or With Pembrolizumab in Advanced Solid Tumors by Papadopoulos, Kyriakos P., Autio, Karen, Golan, Talia, Dobrenkov, Konstantin, Chartash, Elliot, Chen, Qiusheng, Wnek, Richard, Long, Georgina V.

Get full text

Abstract CT042: Pembrolizumab 400 mg Q6W dosing: First clinical outcomes data from Keynote-555 cohort B in metastatic melanoma patients by Lala, Mallika, Akala, Omobolaji, Chartash, Elliot, Kalabis, Mizuho, Su, Shu-Chih, de Alwis, Dinesh, Sinha, Vikram, Jain, Lokesh

“…Abstract Background: Pembrolizumab is approved globally in multiple cancer indications at a dose of 200 mg or 2 mg/kg every three weeks (Q3W). An alternative…”
Get full text

Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma by Cohen, Graham, Rapoport, Bernardo, Chan, Sze W, Ruff, Paul, Arance, Ana, Mujika Eizmendi, Karmele, Houghton, Baerin, Brown, Michael P, Zielinski, Robert M, Muñoz Couselo, Eva, Lyle, Megan, Anderson, James R, Jain, Lokesh, de Alwis, Dinesh, Lala, Mallika, Akala, Omobolaji, Chartash, Elliot, Jacobs, Conrad

“…Intravenous pembrolizumab 400 mg every 6 weeks was approved across tumor types based on pharmacokinetic modeling, which showed exposures consistent with…”
Get full text

A six-weekly (Q6W) dosing schedule for pembrolizumab based on an exposure-response (E-R) evaluation using modeling and simulation by Lala, Mallika, Li, Mengyao, Sinha, Vikram, de Alwis, Dinesh, Chartash, Elliot, Jain, Lokesh

“…Abstract only…”
Get full text

First-in-human phase 1 study of MK-1248, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody, as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors by Geva, Ravit, Voskoboynik, Mark, Beebe, Amy M, Gwo, Jennifer, Dobrenkov, Konstantin, Chartash, Elliot, Long, Georgina V.

“…Abstract only…”
Get full text

Systemic lupus erythematosus complicated by thrombotic microangiopathy by Jain, R, Chartash, E, Susin, M, Furie, R

“…Seven patients with systemic lupus erythematosus (SLE) or SLE-like disease developed thrombotic microangiopathy. Prominent features of their acute illnesses…”
Get more information

Phase 1 study of MK-4166, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) antibody, as monotherapy or with pembrolizumab (pembro) in patients (pts) with advanced solid tumors by Papadopoulos, Kyriakos P., Autio, Karen A., Golan, Talia, Dobrenkov, Konstantin, Chartash, Elliot, Li, Xiaoyun Nicole, Wnek, Richard, Long, Georgina V.

“…Abstract only 9509 Background: Ligation of GITR on immune cells decreases T reg -mediated suppression and enhances T cell proliferation. MK-4166 is a humanized…”
Get full text